## Tab 2

January 25, 2007

Page 1
STATE OF WISCONSIN
CIRCUIT COURT DANE COUNTY
Branch 7
Case No. 04-CV-1709
Unclassified - Civil:30703
------x
STATE OF WISCONSIN,

Plaintiff,

v.

AMGEN INC., et al.,

Defendants.

-----x

830 Third Avenue
New York, New York 10022

January 25th, 2007

11:42 a.m.

HIGHLY CONFIDENTIAL Videotaped Deposition of Defendant SANDOZ, INC., by: HECTOR ARMANDO KELLUM, Thursday, January 25th, 2007, 11:42 a.m. at the offices of Kirby, McInerney and Squire, held before a Notary Public of the State of New York at the above time and place.

10

11

January 25, 2007

Page 38

- A. That time frame spans beyond my direct experience with Sandoz. So, I can't answer it categorically that in every instance that is the case. But I would expect that we have been sending those prices to that pricing compendia for that time frame.
- Q. For what time period are you certain from either your own personal knowledge or inquiry you made to prepare for today's deposition that Sandoz has sent both AWP and WAC to these pricing publications like First Data Bank?
- A. Yeah, in preparing for the deposition, I talked to a couple of people in the company, so I think I would be comfortable saying back to maybe 1999, '98, people have confirmed that that was sort of the practice.
- Q. And can you tell me who you spoke to to get that information?
- A. Yes. I spoke to Ira Beringer.
- Q. What is his current job title?
- A. I believe his title is Director of
  Business Development.

January 25, 2007

Page 56

- my experience, that has been the case. They have
- published the AWP and WAC, that we submitted to
- <sup>3</sup> them.
- Q. And sitting here today, can you identify
- 5 any specific instance in which First Data Bank
- <sup>6</sup> published an AWP or a WAC, for a Sandoz drug that
- was different than the AWP or WAC, that Sandoz
- 8 reported to First Data Bank?
- <sup>9</sup> A. I can't cite a specific instance.
- However, I do or I am aware that from time to time
- there have been discrepancies between what we have
- submitted to them and what they have published.
- Q. Can you describe those instances?
- A. I can't describe them in a lot of detail
- other than, you know, for whatever reason, we have
- gotten inquiries, sometimes from a customer or
- from First Data Bank themselves, asking us to
- verify something. And when we have done that,
- have determined that they did not have the AWP,
- and/or WAC, that we had you know, originally
- submitted to them.
- O. What was the resolution of those

January 25, 2007

Page 57

- discussions? That is, did First Data Bank wind up
- publishing the AWP's and WAC's that you had
- originally sent to it?
- A. I believe after we have confirmed what
- the correct AWP and WAC was, then they published
- those prices. That's my belief.
- Q. Does Sandoz also send WAC's and AWP's to
- 8 the Redbook for Sandoz products?
- 9 MR. GALLAGHER: Objection to the form of
- the question.
- A. Yes, they receive that pricing.
- Q. And are those the same WAC's and AWP's,
- that Sandoz sends to First Data Bank?
- A. Yes.
- MR. GALLAGHER: Objection to the form of
- the question.
- A. Yes, they are the same.
- Q. Has Sandoz ever been asked by First Data
- Bank, Redbook or Medispan, to verify the WAC's and
- AWP's, that those companies publish for Sandoz
- <sup>21</sup> drugs?
- A. In my experience, yes, they have from

January 25, 2007

Page 79

- Q. So, it's your testimony that the AWP,
- for a Sandoz generic drug is always ten percent of
- the AWP, for the corresponding brand name drug?
- MR. GALLAGHER: Objection. Misstates
- $^{5}$  prior testimony.
- A. No, I can't say that. I haven't looked
- at every AWP, for all of the products that you
- have requested. So, it's quite possible that
- there is some that are not a ten present discount.
- I can just say that in today's practice, of what
- I'm doing, that would be our typical methodology
- would be to, if we were launching a generic drug,
- is to price our generic AWP, at a ten percent
- discount to the brand AWP.
- <sup>15</sup> Q. Is that regardless of what the actual
- prices in the marketplace are for Sandoz drugs?
- MR. GALLAGHER: Objection to the form of
- the question.
- A. Can you repeat that question?
- Q. Sure. Is that true that Sandoz will set
- the AWP, for its generic, at the time of launch,
- at ten percent of the brand AWP, regardless of

January 25, 2007

Page 115

- basically, to get them to pay their invoice within
- the terms of the -- our invoices would for example
- say two percent discount if paid within thirty
- days basically net thirty, thirty-one or something
- like that. So if they submit payment for that
- invoice before the 30th day, then they would be
- entitled to a prompt pay discount.
- 8 Q. Now, in those instances in which Sandoz
- <sup>9</sup> sells indirectly to a retail pharmacy through a
- wholesaler and there is a contract between Sandoz
- and the retail pharmacy, the highest price for
- that contract --
- MR. LIBMAN: Strike that. That was a
- mouth full.
- Q. -- in instances in which Sandoz sells
- indirectly to a retail pharmacy through a
- wholesaler and there is a contract in place
- between Sandoz and the retail pharmacy that sets
- the price, that price is always WAC or lower; is
- that correct?
- MR. GALLAGHER: The contract price
- you're talking about?

January 25, 2007

Page 116

- <sup>1</sup> MR. LIBMAN: Yes, sir.
- A. Yes. The contract price in my
- $^3$  experience has -- is typically lower than WAC,
- 4 yes.
- <sup>5</sup> Q. How much lower than WAC, when you say
- 6 typically lower than WAC?
  - A. There is no one answer.
- Q. Can you give me a range?
- $^{9}$  A. Could be -- well a range of the --
- O. Of the percent below WAC that the
- contract price?
- A. -- could be at?
- Q. Yes, sir?
- A. It would depend obviously on the
- particular product and the market for that
- product. So it could range anywhere from, I have
- seen contract prices at WAC. So it could be from
- zero to a discount of maybe eighty to ninety
- percent on the high side.
- Q. How frequently is it the case that the
- percentage discount off WAC in this type of
- transaction is eighty to ninety percent?

January 25, 2007

Page 135

- "FYI, I have also included old and new Cefadroxil
- 2 AWP and WAC. Remember that even though AWP and WAC
- <sup>3</sup> are being adjusted on these products there will be
- 4 no contract price adjustments at this time." Do
- <sup>5</sup> you see that?
- Q. If you look at the next page, which is
- entitled Geneva Pharmaceuticals AWP/WAC changes
- effective January 1, I'm sorry January 21, 2003.
- 10 Cefadroxil is listed at the bottom there the last
- two lines, do you see that?
- A. Yes.
- Q. Do you see by looking across there that
- the new AWP for those two forms of Cefadroxil has
- been increased above the old AWP?
- A. Yes.
- Q. And the same is true that the -- with
- respect to WAC that is the new WAC's for those two
- forms of Cefadroxil, are being increased above the
- old WAC's?
- A. Yes.
- Q. And according to this email, the first

January 25, 2007

Page 136

- page that is being done even though quote "there
- will be no contract price adjustments at this
- time." Do you see that?
- <sup>4</sup> A. Yes.
- <sup>5</sup> MR. GALLAGHER: Objection no foundation.
- MR. LIBMAN: I'm just asking if that's
- what the words say. Is that objectionable?
- 8 MR. GALLAGHER: If that is the question,
- <sup>9</sup> no.
- A. Yes, that's what it says.
- Q. So this is an example of Sandoz raising
- its WAC's and AWP's even though its contract
- prices were not changing; correct?
- MR. GALLAGHER: Let me object to the
- form and object to the fact that I don't believe
- this appears on any of the targeted drug lists for
- any of the states at issue in this deposition.
- A. Okay. The -- it appears you know as he
- says, at this time I guess without -- I didn't
- prepare anything for this obviously. So I don't
- know what additional background there might be if
- he means at this time if he means today, this

January 25, 2007

Page 137

- week. But yet next we're taking contract price
- increases which is a possibility. I don't know
- the whole context and the whole story of what
- 4 might have occurred. So without that, it's really
- hard to say you know, at this time today maybe
- they didn't take the increase. But it's quite
- possible they did this in preparation to do that.
- <sup>8</sup> I don't know that.
- <sup>9</sup> Q. Can you think of any other circumstances
- in which it would be appropriate to raise an AWP
- and a WAC on these drugs, even though the contract
- price was not being adjusted?
- MR. GALLAGHER: Objection to the form of
- the question.
- A. Can you repeat that question?
- Q. Are you aware of any business reason
- that would exist for raising an AWP and a WAC even
- though the contract price is not changing?
- MR. GALLAGHER: Objection to the form of
- the question.
- A. No, I'm not really aware of any. Let me
- add to that. I the only thing I might add would